The European Commission has given its approval to hp 's Jivi treatment for patients with haemophilia . Bayer has now received approval from the US Food and Drug Administration and regulators in Japan . Jivi is the third treatment in Bayer 's haemophilia portfolio . The commission 's approval was based on a study which showed 85 % success in patients treated every five days and a 74 % success rate in those dosed weekly , in terms of bleed protection .
The European Commission has given its approval to Bayer's Jivi treatment for patients with haemophilia A. Bayer has now received approval from the US Food and Drug Administration and regulators in Japan. Jivi is the third treatment in Bayer's haemophilia portfolio. The EU's approval was based on a study which showed 100% success in patients treated every five days and a 74% success rate in those dosed weekly, in terms of bleed protection.